Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Tarih
2014
Yazar
Arena, Francis
Andre, Fabrice
O'Regan, Ruth
Toi, Masakazu
Xu, Binghe
Jerusalem, Guy
Masuda, Norikazu
Wilks, Sharon
Isaacs, Claudine
Yap, Yoon-Sim
Papai, Zsuzsanna
Lang, Istvan
Armstrong, Anne
Lerzo, Guillermo
White, Michelle
Shen, Kunwei
Litton, Jennifer
Chen, David
Zhang, Yufen
Ali, Shyanne
Taran, Tetiana
Gianni, Luca
Ozguroglu, Mustafa
Üst veri
Tüm öğe kaydını göster
Özet
Background Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.
Bağlantı
http://hdl.handle.net/20.500.12627/166870
https://doi.org/10.1016/s1470-2045(14)70138-x
Koleksiyonlar